Status and phase
Conditions
Treatments
About
M108 is a monoclonal antibody specific for gastric and gastroesophageal adenocarcinomas. The aim of this phase I study is to establish safety and Tolerability of different Dosage regimen in patients With Advanced Unresectable Solid Tumors in China.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
152 participants in 2 patient groups
Loading...
Central trial contact
Zhaoyu Jin, Ph.D
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal